SI
LGND icon

Stephens Inc’s Ligand Pharmaceuticals LGND Stock Holding History

Stephens Inc’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$324K Sell
1,625
-31
-2% -$6.13K ﹤0.01% 1008
2025
Q4 		$313K Sell
1,656
-4
-0.2% -$769 ﹤0.01% 1022
2025
Q3 		$294K Buy
+1,660
New +$247K ﹤0.01% 1058
2024
Q2 		– Sell
-1,094
Closed -$80K – 1319
2024
Q1 		$80K Hold
1,094
– – ﹤0.01% 1260
2023
Q4 		$78.1K Sell
1,094
-54
-5% -$3.19K ﹤0.01% 1168
2023
Q3 		$68.8K Sell
1,148
-600
-34% -$39.5K ﹤0.01% 1127
2023
Q2 		$126K Sell
1,748
-40
-2% -$3K ﹤0.01% 1114
2023
Q1 		$132K Buy
1,788
+5
+0.3% +$355 ﹤0.01% 1076
2022
Q4 		$119K Sell
1,783
-1,075
-38% -$69.9K ﹤0.01% 1061
2022
Q3 		$154K Sell
2,858
-77
-3% -$4.53K ﹤0.01% 1053
2022
Q2 		$163K Sell
2,935
-88
-3% -$4.99K ﹤0.01% 1087
2022
Q1 		$212K Sell
3,023
-375
-11% -$27.2K ﹤0.01% 1158
2021
Q4 		$327K Buy
3,398
+128
+4% +$11.8K ﹤0.01% 1014
2021
Q3 		$284K Buy
3,270
+152
+5% +$11.8K ﹤0.01% 1069
2021
Q2 		$255K Buy
3,118
+63
+2% +$5.24K ﹤0.01% 1103
2021
Q1 		$291K Sell
3,055
-2,740
-47% -$259K ﹤0.01% 1014
2020
Q4 		$360K Buy
5,795
+338
+6% +$19.3K 0.01% 866
2020
Q3 		$324K Buy
5,457
+156
+3% +$10.6K 0.01% 849
2020
Q2 		$370K Sell
5,301
-34,841
-87% -$2.21M 0.01% 781
2020
Q1 		$1.82M Sell
40,142
-1,637
-4% -$92.8K 0.05% 362
2019
Q4 		$2.72M Sell
41,779
-2,196
-5% -$147K 0.06% 336
2019
Q3 		$2.73M Sell
43,975
-2,119
-5% -$133K 0.06% 331
2019
Q2 		$3.28M Sell
46,094
-34,359
-43% -$2.53M 0.07% 294
2019
Q1 		$6.31M Buy
80,453
+76,106
+1,751% +$5.77M 0.15% 151
2018
Q4 		$368K Buy
4,347
+1,458
+50% +$155K 0.01% 785
2018
Q3 		$495K Buy
+2,889
New +$436K 0.01% 782
2017
Q3 		– Sell
-2,919
Closed -$221K – 796
2017
Q2 		$221K Buy
2,919
+337
+13% +$23.6K 0.01% 775
2017
Q1 		$171K Buy
2,582
+993
+62% +$65.3K 0.01% 780
2016
Q4 		$101K Buy
1,589
+305
+24% +$19.2K ﹤0.01% 748
2016
Q3 		$82K Buy
1,284
+160
+14% +$11.7K ﹤0.01% 730
2016
Q2 		$84K Buy
1,124
+164
+17% +$12.2K ﹤0.01% 717
2016
Q1 		$64K Hold
960
– – ﹤0.01% 713
2015
Q4 		$65K Buy
960
+56
+6% +$3.46K ﹤0.01% 705
2015
Q3 		$48K Hold
904
– – ﹤0.01% 715
2015
Q2 		$57K Hold
904
– – ﹤0.01% 760
2015
Q1 		$43K Buy
904
+151
+20% +$5.79K ﹤0.01% 781
2014
Q4 		$25K Sell
753
-45
-6% -$1.46K ﹤0.01% 785
2014
Q3 		$23K Buy
798
+223
+39% +$7.4K ﹤0.01% 788
2014
Q2 		$22K Buy
575
+168
+41% +$6.82K ﹤0.01% 815
2014
Q1 		$17K Buy
407
+30
+8% +$1.25K ﹤0.01% 778
2013
Q4 		$12K Buy
377
+72
+24% +$2.35K ﹤0.01% 844
2013
Q3 		$8K Buy
+305
New +$8.58K ﹤0.01% 801

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Stephens Inc's LGND Position: Q1 2026 in Review

Stephens Inc reduced its Ligand Pharmaceuticals (LGND) stake by 1.9% in Q1 2026, selling an estimated $6.13K and leaving 1,625 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

Stephens Inc first reported a position in LGND in Q3 2013 and has held it in 42 quarters since. The position peaked at $6.31M in Q1 2019. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Stephens Inc held 1,625 shares of Ligand Pharmaceuticals worth $324K as of Q1 2026.
  • Stephens Inc sold 31 Ligand Pharmaceuticals shares in Q1 2026, an estimated $6.13K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Stephens Inc's portfolio in Q1 2026, its #1008 holding.
  • Stephens Inc first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 42 quarters since.
  • Stephens Inc's Ligand Pharmaceuticals position peaked at $6.31M in Q1 2019.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Stephens Inc's 13F filing for Q1 2026, filed 28 Apr 2026.